Drug Database
DT
DTPa+Hep-B+IPV vaccine (Infanrix Penta)
✓ ApprovedGSK · Recombinant Proteins · Recombinant Proteins
What is DTPa+Hep-B+IPV vaccine?
DTPa+Hep-B+IPV vaccine is a recombinant proteins developed by GSK. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.
Drug Profile
| Brand Names | Infanrix Penta |
| Company | GSK |
| Drug Class | Recombinant Proteins, Vaccine |
| Route | Injectable (Others), Intramuscular (IM) Injection |
| Status | Approved |
Sources: ClinicalTrials.gov, GSK
Therapeutic Indications
DTPa+Hep-B+IPV vaccine is developed for 5 unique indications across 2 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Infections and infestations | Diphtheria | ✓ Approved |
| Infections and infestations | Hepatitis B | ✓ Approved |
| Infections and infestations | Pertussis | ✓ Approved |
| Infections and infestations | Tetanus | ✓ Approved |
| Surgical and medical procedures | Polio immunisation | ✓ Approved |
Related Research Articles
Unable to load articles right now.